Randomized phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer.

被引：0
|
作者：
Sehouli, J
Sommer, H
Klare, P
Stauch, M
Zeimet, A
Paulenz, A
Renziehausen, K
Keil, E
Lichtenegger, W
Oskay-Ozcelik, G
机构：
[1] Med Univ, Charite, Berlin, Germany
[2] NE German Soc Gynecol Oncol, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5139
引用
收藏
页码：483S / 483S
页数：1
相关论文
共 50 条
  • [1] A randomized multicenter phase III trial of topotecan monotherapy versus topotecan plus etoposide versus topotecan plus gemcitabine for second-line treatment of recurrent ovarian cancer.
    Sehouli, J.
    Sommer, H.
    Klare, P.
    Stauch, M.
    Zeimet, A.
    Paulenz, A.
    Steck, T.
    Riedel, H.
    Keil, E.
    Stengel, D.
    Kuznik, A.
    Lichtenegger, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 263S - 263S
  • [2] Second-line treatment with Topotecan in ovarian cancer
    Morales, S
    Balil, A
    Salud, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S87 - S87
  • [3] Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer A Randomized Clinical Trial
    Takahashi, Nobuyuki
    Hao, Zhonglin
    Villaruz, Liza C.
    Zhang, Jun
    Ruiz, Jimmy
    Petty, W. Jeffrey
    Mamdani, Hirva
    Riess, Jonathan W.
    Nieva, Jorge
    Pachecho, Jose M.
    Fuld, Alexander D.
    Shum, Elaine
    Chauhan, Aman
    Nichols, Samantha
    Shimellis, Hirity
    Mcglone, Jessie
    Sciuto, Linda
    Pinkiert, Danielle
    Graham, Chante
    Shelat, Meenakshi
    Kattappuram, Robbie
    Abel, Melissa
    Schroeder, Brett
    Upadhyay, Deep
    Krishnamurthy, Manan
    Sharma, Ajit Kumar
    Kumar, Rajesh
    Malin, Justin
    Schultz, Christopher W.
    Goyal, Shubhank
    Redon, Christophe E.
    Pommier, Yves
    Aladjem, Mirit I.
    Gore, Steven D.
    Steinberg, Seth M.
    Vilimas, Rasa
    Desai, Parth
    Thomas, Anish
    JAMA ONCOLOGY, 2023, 9 (12) : 1669 - 1677
  • [4] Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
    von Pawel, Joachim
    Jotte, Robert
    Spigel, David R.
    O'Brien, Mary E. R.
    Socinski, Mark A.
    Mezger, Joerg
    Steins, Martin
    Bosquee, Leon
    Bubis, Jeffrey
    Nackaerts, Kristiaan
    Trigo, Jose M.
    Clingan, Philip
    Schuette, Wolfgang
    Lorigan, Paul
    Reck, Martin
    Domine, Manuel
    Shepherd, Frances A.
    Li, Shaoyi
    Renschler, Markus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (35) : 4012 - U160
  • [5] Weekly administration of topotecan–paclitaxel as second-line treatment in ovarian cancer
    G. P. Stathopoulos
    N. A. Malamos
    G. Aravantinos
    S. Rigatos
    Ch. Christodoulou
    J. Stathopoulos
    D. Skarlos
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 123 - 128
  • [6] The role of topotecan as second-line therapy in patients with recurrent ovarian cancer
    Beshara, N
    Fung, MFK
    Faught, W
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2002, 23 (04) : 287 - 290
  • [7] CARDIAC SAFETY OF AMRUBICIN IN A RANDOMIZED PHASE 3 TRIAL OF AMRUBICIN VS TOPOTECAN AS SECOND-LINE TREATMENT FOR SMALL CELL LUNG CANCER (SCLC)
    Spigel, David R.
    Von Pawel, Joachim
    Jotte, Robert
    Socinski, Mark A.
    O'Brien, Mary E. R.
    Mcnally, Richard
    Renschler, Markus
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S309 - S309
  • [8] Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial
    Baize, N.
    Monnet, I.
    Greillier, L.
    Geier, M.
    Lena, H.
    Janicot, H.
    Vergnenegre, A.
    Crequit, J.
    Lamy, R.
    Auliac, J. B.
    Le Treut, J.
    Le Caer, H.
    Gervais, R.
    Dansin, E.
    Madroszyk, A.
    Renault, P.
    Legarff, G.
    Schott, R.
    Saulnier, P.
    Chouaid, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S246 - S246
  • [9] Topotecan (Hycamtin) - A new second-line agent for ovarian cancer
    不详
    AMERICAN JOURNAL OF NURSING, 1997, 97 (12) : 59 - 59
  • [10] Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).
    Jotte, R.
    Von Pawel, J.
    Spigel, D. R.
    Socinski, M. A.
    O'Brien, M.
    Paschold, E. H.
    Mezger, J.
    Steins, M.
    Bosquee, L.
    Bubis, J. A.
    Nackaerts, K.
    Perez, J. M. Trigo
    Clingan, P. R.
    Schuette, W.
    Lorigan, P.
    Reck, M.
    Domine, M.
    Shepherd, F. A.
    McNally, R.
    Renschler, M. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345